H.C. Wainwright Reiterates Buy Rating on Mineralys Therapeutics, Inc. (MLYS)

H.C. Wainwright analyst Matthew Caufield reiterated a Buy rating and $56.00 price target on Mineralys Therapeutics, Inc. (NASDAQ: MLYS).

The analyst commented: 'Mineralys Therapeutics presented new data for aldosterone synthase inhibitor (ASI) lorundrostat at the American Heart Association (AHA) Hypertension Scientific Sessions 2026, adding to the clinical evidence supporting lorundrostat’s potential in difficult-to-treat hypertension. We view the latest findings as constructive ahead of the approaching December 22, 2026, PDUFA, supporting lorundrostat’s profile for delivering clinically meaningful BP reductions in patients who remain above target despite multiple standard anti-hypertensive therapies. Importantly, the new Launch-HTN analysis provides a more tangible perspective on the proportion of patients who could achieve guideline-recommended BP control, while the Explore-OSA results extend the BP-lowering relevance for potential broader future upside. Notably, the absence of a measurable change in apnea-hypopnea indices tempers the potential implications for OSA-specific treatment, in our view. With our near-term thesis still centered on prospective FDA approval and commercial launch in uncontrolled and resistant hypertension, we believe the latest data provide consistent support for lorundrostat’s clinical profile, and we reiterate our Buy rating and $56 price target."

For an analyst ratings summary and ratings history on Mineralys Therapeutics, Inc. click here. For more ratings news on Mineralys Therapeutics, Inc. click here.

Shares of Mineralys Therapeutics, Inc. closed at $23.37 yesterday.

You May Also Be Interested In

• RBC Capital on Mirum (MIRM): 'we could see MIRM shares up 5–10% on the EXPAND news'
• Biogen (BIIB) PT Raised to $220 at BMO Capital
• Jefferies: 'we estimate that Starlink is on 9% of aircraft today and will be on 23% by 2028'